EMA — authorised 16 July 2021
- Marketing authorisation holder: ALMIRALL S.A.
- Status: approved
EMA authorised Klisyri on 16 July 2021
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA authorised it on 16 July 2021.
ALMIRALL S.A. holds the EU marketing authorisation.